Atara Biotherapeutics (ATRA) News Today $12.00 -0.77 (-6.03%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Canaccord Genuity Group Increases Atara Biotherapeutics (NASDAQ:ATRA) Price Target to $21.00November 17 at 2:30 AM | americanbankingnews.comEcoR1 Capital, LLC Increases Stake in Atara Biotherapeutics IncNovember 15 at 8:01 AM | gurufocus.comAtara Biotherapeutics to Participate at the Stifel 2024 Healthcare ConferenceNovember 13, 2024 | businesswire.comAtara Biotherapeutics (NASDAQ:ATRA) Stock Price Expected to Rise, Canaccord Genuity Group Analyst SaysCanaccord Genuity Group boosted their price target on shares of Atara Biotherapeutics from $13.00 to $21.00 and gave the stock a "buy" rating in a research report on Wednesday.November 13, 2024 | marketbeat.comInsights into Atara Biotherapeutics's Upcoming EarningsNovember 11, 2024 | benzinga.comAtara Biotherapeutics (ATRA) Set to Announce Earnings on TuesdayNovember 10, 2024 | americanbankingnews.comAtara Biotherapeutics (ATRA) to Release Earnings on TuesdayAtara Biotherapeutics (NASDAQ:ATRA) will be releasing earnings after the market closes on Tuesday, November 12, Zacks reports.November 6, 2024 | marketbeat.comAtara Biotherapeutics (NASDAQ:ATRA) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comAtara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | finance.yahoo.comAtara Biotherapeutics (ATRA) Stock Is Up 20%: What's Going On?September 4, 2024 | msn.comAtara Biotherapeutics Shares Climb on $36 Million Direct OfferingSeptember 3, 2024 | marketwatch.comAtara Biotherapeutics Announces $36 Million Registered Direct OfferingSeptember 3, 2024 | finance.yahoo.comAtara Biotherapeutics, Inc. (NASDAQ:ATRA) EVP Sells $12,073.23 in StockAugust 21, 2024 | insidertrades.comAtara Biotherapeutics (ATRA) Gets a Hold from Stifel NicolausAugust 19, 2024 | markets.businessinsider.comMizuho Upgrades Atara Biotherapeutics (ATRA)August 17, 2024 | msn.comAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Just Reported Earnings, And Analysts Cut Their Target PriceAugust 15, 2024 | uk.finance.yahoo.comAtara Biotherapeutics Second Quarter 2024 Earnings: Misses ExpectationsAugust 14, 2024 | finance.yahoo.comATRA Stock Earnings: Atara Biotherapeutics Misses EPS, Misses Revenue for Q2 2024August 12, 2024 | msn.comTSX inches up; investors cautious ahead of US dataAugust 12, 2024 | msn.comStock market today: Nasdaq edges higher, Dow drops as investors await key signals on inflation, economyAugust 12, 2024 | ca.finance.yahoo.comNickelodeon Marketing Exec Sabrina Caluori Exiting Ahead Of Broader Paramount LayoffsAugust 12, 2024 | nz.finance.yahoo.comAtara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership UpdateAugust 12, 2024 | finance.yahoo.comAtara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth ConferenceAugust 7, 2024 | finance.yahoo.comAtara Biotherapeutics Inc (ATRA) Earnings Dates & ReportsAugust 6, 2024 | investing.comAtara Biotherapeutics, Inc. (AT20.F)August 5, 2024 | uk.finance.yahoo.comAT20.MU,0P0001LALG,0 (AT20.MU)August 4, 2024 | uk.finance.yahoo.comAtara Biotherapeutics (NASDAQ:ATRA) Stock, Short Interest ReportAugust 1, 2024 | benzinga.comAtara Biotherapeutics Receives Buy Rating Amidst Positive FDA Review and Solid Financial OutlookJuly 19, 2024 | markets.businessinsider.comAtara lead asset tab-cel undergoes FDA priority reviewJuly 19, 2024 | msn.comThe Goldman Sachs Group Trims Atara Biotherapeutics (NASDAQ:ATRA) Target Price to $11.00The Goldman Sachs Group decreased their price target on shares of Atara Biotherapeutics from $12.50 to $11.00 and set a "sell" rating on the stock in a research note on Wednesday.July 17, 2024 | marketbeat.comAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Average Rating of "Hold" by BrokeragesShares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) have earned a consensus recommendation of "Hold" from the three research firms that are currently covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating. The average 12-montJuly 16, 2024 | marketbeat.comAtara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 5, 2024 | businesswire.comAtara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy ForumJuly 3, 2024 | businesswire.comAtara Biotherapeutics' Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare DiseasesJune 21, 2024 | businesswire.comAtara Biotherapeutics (NASDAQ:ATRA) Sees Strong Trading VolumeAtara Biotherapeutics (NASDAQ:ATRA) Sees Unusually-High Trading VolumeJune 21, 2024 | marketbeat.comAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Consensus Rating of "Hold" by BrokeragesShares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) have earned an average rating of "Hold" from the three brokerages that are currently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation. The average 1June 21, 2024 | marketbeat.comAtara Biotherapeutics (NASDAQ:ATRA) Shares Gap Down to $9.87Atara Biotherapeutics (NASDAQ:ATRA) Shares Gap Down to $9.87June 20, 2024 | marketbeat.comAtara Biotherapeutics (NASDAQ:ATRA) Shares to Reverse Split on Thursday, June 20thAtara Biotherapeutics, Inc. (NASDAQ:ATRA - Free Report)'s stock is set to reverse split before the market opens on Thursday, June 20th. The 1-25 reverse split was announced on Thursday, June 20th. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, June 20th.June 18, 2024 | marketbeat.comAtara Biotherapeutics Announces 1-for-25 Reverse Stock SplitJune 17, 2024 | businesswire.comAtara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 7, 2024 | businesswire.comAtara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceJune 5, 2024 | businesswire.comAtara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual MeetingMay 29, 2024 | businesswire.comQ2 2024 EPS Estimates for Atara Biotherapeutics, Inc. Boosted by Analyst (NASDAQ:ATRA)Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Free Report) - Stock analysts at HC Wainwright upped their Q2 2024 earnings per share estimates for shares of Atara Biotherapeutics in a research report issued to clients and investors on Wednesday, May 22nd. HC Wainwright analyst R. Burns now anticipateMay 24, 2024 | marketbeat.comAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Expected to Post Q1 2025 Earnings of ($0.27) Per ShareAtara Biotherapeutics, Inc. (NASDAQ:ATRA - Free Report) - Analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Atara Biotherapeutics in a research note issued on Wednesday, May 22nd. HC Wainwright analyst R. Burns expects that the biotechnology company wMay 23, 2024 | marketbeat.comHC Wainwright Reaffirms "Neutral" Rating for Atara Biotherapeutics (NASDAQ:ATRA)HC Wainwright reiterated a "neutral" rating on shares of Atara Biotherapeutics in a report on Wednesday.May 22, 2024 | marketbeat.comEric J. Hyllengren Sells 28,648 Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) StockMay 21, 2024 | insidertrades.comAtara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Pascal Touchon Sells 81,506 SharesMay 21, 2024 | insidertrades.comAtara Biotherapeutics, Inc. (NASDAQ:ATRA) CFO Eric J. Hyllengren Sells 28,648 SharesAtara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) CFO Eric J. Hyllengren sold 28,648 shares of the company's stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $0.62, for a total transaction of $17,761.76. Following the completion of the sale, the chief financial officer now directly owns 645,671 shares in the company, valued at $400,316.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.May 20, 2024 | marketbeat.comAtara Biotherapeutics Files Biologics License Application for Tabelecleucel with FDA; Shares RiseMay 20, 2024 | finance.yahoo.comAtara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDAMay 20, 2024 | businesswire.com Get Atara Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter. Email Address JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad)Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback. Get your free guide NOW before it's too late. ATRA Media Mentions By Week ATRA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATRA News Sentiment▼0.600.56▲Average Medical News Sentiment ATRA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATRA Articles This Week▼81▲ATRA Articles Average Week Get Atara Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ALVR News SCLX News OGI News GOSS News ELDN News MDWD News DMAC News BDTX News ATAI News LFVN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATRA) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atara Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atara Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
